Donate Help Contact The AHA Sign In Home
American Heart Association
Hypertension
Search: search_blue_button Advanced Search
Hypertension. 2000;35:329-336

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Barton, M.
Right arrow Articles by Shaw, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Barton, M.
Right arrow Articles by Shaw, S.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*CHOLESTEROL
*INDOMETHACIN
Medline Plus Health Information
*Obesity
Related Collections
Right arrow Obesity
Right arrow ACE/Angiotension receptors
Right arrow Angiogenesis
Right arrow Animal models of human disease
Right arrow Other hypertension
Right arrow Gene expression
Right arrow Other Treatment
Right arrow Endothelium/vascular type/nitric oxide
Right arrow Other Vascular biology

(Hypertension. 2000;35:329.)
© 2000 American Heart Association, Inc.


Scientific Contributions

Obesity Is Associated With Tissue-Specific Activation of Renal Angiotensin-Converting Enzyme In Vivo

Evidence for a Regulatory Role of Endothelin

Presented in part at the Gordon Research Conference on Angiotensin, Queen’s College, Oxford, UK, August 8–13, 1999.

Matthias Barton; Renata Carmona; Henning Morawietz; Livius V. d’Uscio; Winfried Goettsch; Heinz Hillen; Christian C. Haudenschild; Jose E. Krieger; Klaus Münter; Thomas Lattmann; Thomas F. Lüscher; Sidney Shaw

From the Cardiology section, Department of Medicine (M.B., L.V.d’U., T.L., T.F.L.), University Hospital Zürich, and Cardiovascular Research Laboratory (M.B., L.V.d’U., T.L., T.F.L.), Institute of Physiology, University of Zürich, Switzerland; Laboratory of Genetics and Molecular Cardiology (R.C., J.E.K.), Heart Institute, University of São Paolo School of Medicine, São Paulo, Brazil; Institute of Pathophysiology (H.M., W.G.), Faculty of Medicine, Martin-Luther University Halle-Wittenberg, Halle, Germany; Central Laboratory (H.H.), BASF Pharma, Ludwigshafen, Germany; Preclinical Cardiology, Knoll AG, Ludwigshafen (K.M.), Germany; Experimental Pathology (C.C.H.), Jerome H. Holland Laboratory, Rockville, Md; and Department of Clinical Research (S.S.), University of Bern, Switzerland.

Correspondence to Matthias Barton, MD, Division of Cardiology, Department of Medicine, University Hospital, CH-8091 Zürich, Switzerland. E-mail matthiasbarton{at}compuserve.com

Abstract—In the C57BL/6J mice model, we investigated whether obesity affects the function or expression of components of the tissue renin-angiotensin system and whether endothelin (ET)-1 contributes to these changes. ACE activity (nmol · L His-Leu · mg protein-1) was measured in lung, kidney, and liver in control (receiving standard chow) and obese animals treated for 30 weeks with a high-fat, low cholesterol diet alone or in combination with LU135252, an orally active ETA receptor antagonist. ACE mRNA expression was measured in the kidney, and the effects of LU135252 on purified human ACE were determined. Aortic and renal tissue ET-1 protein content was measured, and the vascular contractility to angiotensin II was assessed. Obesity was associated with a tissue-specific increase in ACE activity in the kidney (55±4 versus 33±3 nmol/L) but not in the lung (34±2 versus 32±2 nmol/L). Long-term LU135252 treatment completely prevented this activation (13.3±0.3 versus 55±4 nmol/L, P<0.05) independent of ACE mRNA expression, body weight, or renal ET-1 protein but did not affect pulmonary or hepatic ACE activity. Obesity potentiated contractions in response to angiotensin II in the aorta (from 6±2% to 33±5% KCl) but not in the carotid artery (4±1% to 3.6±1% KCl), an effect that was completely prevented with LU135252 treatment (6±0.4% versus 33±5% KCl). No effect of LU135252 on purified ACE was observed. Thus, obesity is associated with the activation of renal ACE in vivo independent of its mRNA expression and enhanced vascular contractility to angiotensin II. These effects are regulated by ET in an organ-specific manner, providing novel mechanisms by which ET antagonists may exert organ protection.


Key Words: risk factors • aorta • carotid arteries • vasoconstriction • diet • cholesterol • gene expression




This article has been cited by other articles:


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
M. Barton, E. Haas, and I. Bhattacharya
Getting Radical About Obesity: New Links Between Fat and Heart Disease
Arterioscler Thromb Vasc Biol, April 1, 2009; 29(4): 447 - 448.
[Full Text] [PDF]


Home page
EndocrinologyHome page
T. Wada, S. Ohshima, E. Fujisawa, D. Koya, H. Tsuneki, and T. Sasaoka
Aldosterone Inhibits Insulin-Induced Glucose Uptake by Degradation of Insulin Receptor Substrate (IRS) 1 and IRS2 via a Reactive Oxygen Species-Mediated Pathway in 3T3-L1 Adipocytes
Endocrinology, April 1, 2009; 150(4): 1662 - 1669.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
G. E. Umpierrez, D. Smiley, G. Robalino, L. Peng, A. E. Kitabchi, B. Khan, A. Le, A. Quyyumi, V. Brown, and L. S. Phillips
Intravenous Intralipid-Induced Blood Pressure Elevation and Endothelial Dysfunction in Obese African-Americans with Type 2 Diabetes
J. Clin. Endocrinol. Metab., February 1, 2009; 94(2): 609 - 614.
[Abstract] [Full Text] [PDF]


Home page
PhysiologyHome page
A. M. Jonk, A. J. H. M. Houben, R. T. de Jongh, E. H. Serne, N. C. Schaper, and C. D. A. Stehouwer
Microvascular Dysfunction in Obesity: A Potential Mechanism in the Pathogenesis of Obesity-Associated Insulin Resistance and Hypertension
Physiology, August 1, 2007; 22(4): 252 - 260.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
A. E. Silver, S. D. Beske, D. D. Christou, A. J. Donato, K. L. Moreau, I. Eskurza, P. E. Gates, and D. R. Seals
Overweight and Obese Humans Demonstrate Increased Vascular Endothelial NAD(P)H Oxidase-p47phox Expression and Evidence of Endothelial Oxidative Stress
Circulation, February 6, 2007; 115(5): 627 - 637.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
A. L. Mundy, E. Haas, I. Bhattacharya, C. C. Widmer, M. Kretz, R. Hofmann-Lehmann, R. Minotti, and M. Barton
Fat intake modifies vascular responsiveness and receptor expression of vasoconstrictors: Implications for diet-induced obesity
Cardiovasc Res, January 15, 2007; 73(2): 368 - 375.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
S. B. Ahmed, N. D.L. Fisher, R. Stevanovic, and N. K. Hollenberg
Body Mass Index and Angiotensin-Dependent Control of the Renal Circulation in Healthy Humans
Hypertension, December 1, 2005; 46(6): 1316 - 1320.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
F. J. Warner, R. A. Lew, A. I. Smith, D. W. Lambert, N. M. Hooper, and A. J. Turner
Angiotensin-converting Enzyme 2 (ACE2), But Not ACE, Is Preferentially Localized to the Apical Surface of Polarized Kidney Cells
J. Biol. Chem., November 25, 2005; 280(47): 39353 - 39362.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
S. Engeli, J. Bohnke, K. Gorzelniak, J. Janke, P. Schling, M. Bader, F. C. Luft, and A. M. Sharma
Weight Loss and the Renin-Angiotensin-Aldosterone System
Hypertension, March 1, 2005; 45(3): 356 - 362.
[Abstract] [Full Text] [PDF]


Home page
Hum Mol GenetHome page
H. Katzov, A. M. Bennet, P. Kehoe, B. Wiman, M. Gatz, K. Blennow, B. Lenhard, N. L. Pedersen, U. de Faire, and J. A. Prince
A cladistic model of ACE sequence variation with implications for myocardial infarction, Alzheimer disease and obesity
Hum. Mol. Genet., November 1, 2004; 13(21): 2647 - 2657.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
M. Ye, J. Wysocki, P. Naaz, M. R. Salabat, M. S. LaPointe, and D. Batlle
Increased ACE 2 and Decreased ACE Protein in Renal Tubules From Diabetic Mice: A Renoprotective Combination?
Hypertension, May 1, 2004; 43(5): 1120 - 1125.
[Abstract] [Full Text] [PDF]


Home page
J. Nutr.Home page
R. J. FitzGerald, B. A. Murray, and D. J. Walsh
Hypotensive Peptides from Milk Proteins
J. Nutr., April 1, 2004; 134(4): 980S - 988S.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
J. D. Morrow
Is Oxidant Stress a Connection Between Obesity and Atherosclerosis?
Arterioscler Thromb Vasc Biol, March 1, 2003; 23(3): 368 - 370.
[Full Text] [PDF]


Home page
EndocrinologyHome page
A. Fortuno, A. Rodriguez, J. Gomez-Ambrosi, P. Muniz, J. Salvador, J. Diez, and G. Fruhbeck
Leptin Inhibits Angiotensin II-Induced Intracellular Calcium Increase and Vasoconstriction in the Rat Aorta
Endocrinology, September 1, 2002; 143(9): 3555 - 3560.
[Abstract] [Full Text] [PDF]


Home page
PhysiologyHome page
P. Schling and G. Loffler
Cross Talk Between Adipose Tissue Cells: Impact on Pathophysiology
Physiology, June 1, 2002; 17(3): 99 - 104.
[Abstract] [Full Text] [PDF]


Home page
Journal of Renin-Angiotensin-Aldosterone SystemHome page
A. M Sharma and S. Engeli
The renin-angiotensin system in obesity hypertension
Journal of Renin-Angiotensin-Aldosterone System, March 1, 2001; 2(1_suppl): S114 - S119.
[PDF]


Home page
CirculationHome page
T. F. Luscher and M. Barton
Endothelins and Endothelin Receptor Antagonists : Therapeutic Considerations for a Novel Class of Cardiovascular Drugs
Circulation, November 7, 2000; 102(19): 2434 - 2440.
[Abstract] [Full Text] [PDF]